For more than two decades, many women have approached menopausal hormone therapy with fear, largely because of headlines that followed the 2002 Women's Health Initiative (WHI). But the original study was more nuanced than the message many women received. The WHI actually included two different hormone therapy trials, involving different groups of women and producing different breast cancer outcomes.
In this episode, we take a closer look at what the WHI actually found, what decades of follow-up research have revealed, and why recent FDA labeling changes are reopening the conversation around menopausal hormone therapy. Rather than relying on frightening headlines or broad statements about estrogen and breast cancer, women deserve a more individualized discussion based on the type of hormone therapy, absolute risk, age, timing, symptoms, and personal medical history.
What You’ll Learn by Listening
- The two WHI arms: Which women received estrogen alone, which received estrogen plus a synthetic progestin, and why having a uterus changes the treatment plan.
- The breast-cancer findings: Why long-term randomized follow-up showed roughly a 22% lower breast-cancer incidence with estrogen alone after hysterectomy, compared with roughly a 28% higher incidence with conjugated estrogen plus medroxyprogesterone acetate.
- Incidence versus mortality: Why a change in the number of diagnoses is not automatically the same as a change in deaths from breast cancer.
- Relative versus absolute risk: How a dramatic percentage can translate into a much smaller change in the number of women affected.
- What changed at the FDA: Which boxed-warning statements were removed from updated labels and which important endometrial-cancer warning remains for systemic estrogen used without uterine protection.
- What the FDA update does not mean: It does not mean hormone therapy is right for every woman or that its risks disappeared; it means the risk discussion should be more accurate and individualized.
- Why timing matters: How age and the number of years since menopause can change the benefit-risk conversation.
- Questions to take to your appointment: How to ask which evidence applies to you, request absolute numbers, clarify the type of progestogen being discussed, and understand how your medical history affects the decision.
Questions to Ask Your Clinician
- Which WHI trial arm is most relevant to me—estrogen alone or estrogen plus a progestogen?
- Do I still have my uterus, and what uterine protection would I need if I use systemic estrogen?
- Can you explain my risk in absolute numbers, such as cases per 1,000 women, rather than only a relative percentage?
- How do my age and the number of years since my final menstrual period affect the benefit-risk balance?
- Are there reasons hormone therapy may not be appropriate for me based on my personal or family history?
- Which route, dose, and formulation best fit my symptoms and risk profile, and how will we monitor treatment?
For relevant patient links and research referenced in this episode, please go to our website here for more information: https://wisconsinfunctionalmed.com/podcast/
*********************
Midlife Clarity with Dr. Tracy Page is a podcast for women over 40 navigating hormones, metabolism, strength, and healthy aging during midlife, perimenopause, and menopause.
Connect with Dr. Page:
DISCLAIMER: The information shared on this podcast is for educational purposes only and is not intended as medical advice. It does not replace a consultation with your own physician or qualified health care provider. Always seek professional medical guidance regarding your personal health concerns.
© 2026 Dr. Tracy Page
